Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
Level 5 - mechanism / opinion, no new human data
Narrative review of approved prescription omega-3 formulations and clinical trials without systematic review or meta-analytic pooling
PubMed 25387209 · doi:10.3810/pgm.2014.11.2828
What was done
This narrative review summarizes the efficacy, safety, and clinical considerations of six FDA-approved prescription omega-3 fatty acid products for hypertriglyceridemia, comparing EPA/DHA combinations (omega-3-acid ethyl esters, omega-3-carboxylic acids) with pure EPA (icosapent ethyl).
What was found
The abstract reports no numerical data. It qualitatively notes that all approved prescription omega-3 formulations effectively reduce triglycerides, with magnitude dependent on baseline levels. Products containing DHA can increase low-density lipoprotein cholesterol, whereas icosapent ethyl does not.
Why it matters
It highlights a key differential effect on LDL cholesterol between EPA-only and DHA-containing omega-3 formulations in patients treated for hypertriglyceridemia.
Limits
The abstract provides no quantitative effect sizes, sample sizes, or formal systematic review methodology. Long-term cardiovascular outcome trials for some reviewed formulations were incomplete at the time of publication.
Cited by
- supports Lovaza is an ethyl ester mixture of EPA and DHA, while Vascepa is an EPA-only ethyl ester formulation.